Clinical Notes
A retrospective study of 2 or 3 mg/kg/day propranolol for infantile hemangioma
Kohei Goto,
Kohei Goto
Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu University, Gifu, Japan
Search for more papers by this author Michio Ozeki,
Corresponding Author
Michio Ozeki
Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu University, Gifu, Japan
Correspondence: Michio Ozeki, MD PhD, Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan. Email: [email protected]
Search for more papers by this author Shiho Yasue,
Shiho Yasue
Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu University, Gifu, Japan
Search for more papers by this author Saori Endo,
Saori Endo
Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu University, Gifu, Japan
Search for more papers by this author Toshiyuki Fukao,
Toshiyuki Fukao
Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu University, Gifu, Japan
Search for more papers by this author
Kohei Goto,
Kohei Goto
Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu University, Gifu, Japan
Search for more papers by this author Michio Ozeki,
Corresponding Author
Michio Ozeki
Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu University, Gifu, Japan
Correspondence: Michio Ozeki, MD PhD, Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan. Email: [email protected]
Search for more papers by this author Shiho Yasue,
Shiho Yasue
Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu University, Gifu, Japan
Search for more papers by this author Saori Endo,
Saori Endo
Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu University, Gifu, Japan
Search for more papers by this author Toshiyuki Fukao,
Toshiyuki Fukao
Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu University, Gifu, Japan
Search for more papers by this author
First published: 03 June 2020
No abstract is available for this article.
Disclosure
Michio Ozeki has received honoraria (lecture and adviser fee) from Maruho Co., Ltd. The other authors declare no conflict of interest.
References
- 1Droitcourt C, Kerbrat S, Rault C et al. Safety of oral propranolol for infantile hemangioma. Pediatrics 2018; 141: e20173783.
- 2Ren W, Li S, Gao L et al. Low-dose propranolol for infantile hemangioma of the head and neck: Analysis of 23 consecutive patients. Pediatr. Int. 2017; 59: 213–7.
- 3Ozeki M, Nozawa A, Hori T et al. Propranolol for infantile hemangioma: Effect on plasma vascular endothelial growth factor. Pediatr. Int. 2016; 58: 1130–5.
- 4Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N. Engl. J. Med. 2015; 372: 735–46.
- 5Del Frari L, Léauté-Labrèze C, Guibaud L et al. Propranolol pharmacokinetics in infants treated for Infantile Hemangiomas requiring systemic therapy: Modeling and dosing regimen recommendations. Pharmacol. Res. Perspect. 2018; 30: e00399.
